FDA
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Entrada Therapeutics (TRDA)
-
-
-
-
-
-
-
Entrada Therapeutics (TRDA) Announces FDA Removal of Clinical Hold on ENTR-601-44
-
-
-
-
-
-
-
Entrada Therapeutics Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1
-
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

